160
Taysha Gene Therapies, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
Assets
(positive)
Change from FY21 to FY25
millions USD
FY21:
FY22:
96.4
FY23:
150
FY24:
142
FY25:
325
(positive)
Change from FY21 to FY25
millions USD
FY21:
54.4
FY22:
29.9
FY23:
22.9
FY24:
18.2
FY25:
18.7
Total assets
Change from FY21 to FY25
millions USD
FY21:
214
FY22:
126
FY23:
173
FY24:
160
FY25:
343
Liabilities & Equity
(negative)
Change from FY21 to FY25
millions USD
FY21:
51.7
FY22:
62.8
FY23:
36.8
FY24:
26.2
FY25:
26.6
(negative)
Change from FY21 to FY25
millions USD
FY21:
66.8
FY22:
62.5
FY23:
61.0
FY24:
62.6
FY25:
69.8
(positive)
Change from FY21 to FY25
millions USD
FY21:
95.4
FY22:
0.95
FY23:
74.9
FY24:
71.5
FY25:
247
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
214
FY22:
126
FY23:
173
FY24:
160
FY25:
343
All amounts in millions USD